<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496585</url>
  </required_header>
  <id_info>
    <org_study_id>14-167</org_study_id>
    <nct_id>NCT02496585</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis</brief_title>
  <official_title>Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib&#xD;
      in combination with steroids, has on the lungs. Furthermore, such treatments' side effects&#xD;
      will be studied together with quality of life. In addition, the investigators would like to&#xD;
      determine whether they can find markers in the blood which predict worsening lung injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who are free from pulmonary exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>An acute exacerbation will be defined as (all criteria must be met):&#xD;
Unexplained worsening or development of cough, dyspnea, hypoxia, or pneumonitis lasting more than 4 days&#xD;
New or worsening diffuse pulmonary infiltrates on chest CT (with or without contrast) or new high resolution CT parenchymal abnormalities without significant pneumothorax or pleural effusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Metastases</condition>
  <arm_group>
    <arm_group_label>Nintedanib + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The initial dose of nintedanib will be 150mg two times per day orally according to study protocol. Nintedanib will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo will be taken for 12 weeks. Patients will be given a prednisone taper (40mg prednisone daily for 2 weeks, followed by a strict dose taper of 10mg every 2 weeks for 4 weeks, followed by 10mg for one week and 5mg for one week, for a total duration on prednisone of 8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <arm_group_label>Nintedanib + Prednisone</arm_group_label>
    <other_name>BIBF 1120</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Nintedanib + Prednisone</arm_group_label>
    <arm_group_label>Placebo + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically proven primary thoracic or breast malignancy, lymphoma or&#xD;
             lung metastases (which are not required to be biopsy-proven) treated with definitive&#xD;
             intent at MSK&#xD;
&#xD;
          -  Prior treatment with thoracic radiotherapy completed &gt;4 weeks and ≤ 9 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Radiographic evidence of radiation pneumonitis on a CT scan of the chest with or&#xD;
             without contrast&#xD;
&#xD;
          -  Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE&#xD;
             version 4.0 criteria&#xD;
&#xD;
          -  Age≥18 years&#xD;
&#xD;
          -  KPS &gt; 70%&#xD;
&#xD;
          -  Reduction of any acute toxicity from radiation treatment to grade 1&#xD;
&#xD;
          -  Written informed consent signed prior to entry into the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current oral steroid use &gt; 4 weeks prior to registration&#xD;
&#xD;
          -  Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for&#xD;
             this malignancy, except the following therapies which are permitted: Pembrolizumab,&#xD;
             Nivolumab, Afatinib and all hormonal therapies.&#xD;
&#xD;
          -  Mean esophageal radiation dose &gt;45 Gy&#xD;
&#xD;
          -  Diagnosis of diffuse radiation pneumonitis&#xD;
&#xD;
          -  Untreated or symptomatic brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  Liver metastases&#xD;
&#xD;
          -  Other active malignancies requiring oncologic treatment (Note: non-melanoma skin&#xD;
             cancer, superficial bladder cancer etc. are eligible)&#xD;
&#xD;
          -  Radiographic evidence of cavitary or necrotic tumor and local invasion of major blood&#xD;
             vessels&#xD;
&#xD;
          -  Active chronic Hepatitis C and/or B infection&#xD;
&#xD;
          -  Gastrointestinal disorders that would interfere with drug absorption&#xD;
&#xD;
          -  AST &gt; 1.5 x ULN, ALT&gt;1.5 x ULN and Bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  ≥ Grade 2 proteinuria, creatinine &gt;1.5x ULN or GFR &lt;45 ml/min&#xD;
&#xD;
          -  Other investigational therapy received within 8 weeks prior to screening visit&#xD;
&#xD;
          -  Pregnant women or women who are breast feeding or of child bearing potential not using&#xD;
             a highly effective method of birth control for at least one month prior to enrollment1&#xD;
&#xD;
          -  Sexually active males not committing to birth control during the course of the study&#xD;
             (except if their partner is not of childbearing potential)&#xD;
&#xD;
          -  Conditions that may affect the patient's ability to participate in this trial, e.g.&#xD;
             known or suspected active alcohol or drug abuse&#xD;
&#xD;
          -  Inherited predisposition to bleeding or thrombosis, INR &gt;2, PT and PTT &gt;1.5x ULN&#xD;
&#xD;
          -  History of bleeding disorders or thrombotic events, e.g. hemorrhagic or thrombotic&#xD;
             events within 12 months, clinically significant or tumor-related hemoptysis, active&#xD;
             gastrointestinal bleeding or ulcers or major injuries or surgery&#xD;
&#xD;
          -  ANC &lt; 1.5 K/mcL, Platelets &lt; 100 K/mcL, Hemoglobin &lt; 9.0 g/dl&#xD;
&#xD;
          -  Concomitant treatment with any of the following drugs: azathioprine, cyclophosphamide,&#xD;
             cyclosporine, pirfenidone, full dose anticoagulation (vitamin K antagonists,&#xD;
             dabigatran, heparin, etc.), fibrinolysis and high dose anti-platelet therapy (ex.&#xD;
             Plavix 150mg)^2 Myocardial infarction or unstable angina within 6 or 1 month of&#xD;
             starting nintedanib treatment, respectively&#xD;
&#xD;
          -  Known inherited predisposition to thrombosis&#xD;
&#xD;
          -  Patient with a history of a thrombotic event within 12 months of starting nintedanib&#xD;
             treatment&#xD;
&#xD;
          -  Known predisposition to bleeding&#xD;
&#xD;
          -  Patients with severe hepatic impairment&#xD;
&#xD;
          -  History of a gastrointestinal perforation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Rimner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital (Data Collection Only)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network (Data Collection Only)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD ANDERSON CANCER CENTER (Data Collection Only)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Myriad Genetic Laboratory (Data or Specimen Analysis Only)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nintedanib (BIBF 1120)</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Radiation Pneumonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

